Sign inJoin waitlistJoin the waitlist

Shubham Pant

Professor of · University of Texas M D Anderson Cancer Center

Credentials: · · · · · ·

History

University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

Ohio State University College of Medicine
2005–2008
University of Oklahoma Health Sciences Center
2002–2005
Internal Medicine
2001–2004
Doctor of Medicine
1997–2001

Research

NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial
The Lancet · 2023 · 424 citations
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials
Nature Medicine · 2023 · 334 citations
First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors
EClinicalMedicine · 2021 · 276 citations

Funda Meric-Bernstam
36 papers
Milind Javle
36 papers
David Hong
32 papers
Vivek Subbiah
31 papers
Aung Naing
30 papers
Robert Wolff
28 papers
Sarina Piha-Paul
27 papers
Siqing Fu
25 papers
DK
Daniel Karp
23 papers
Apostolia Tsimberidou
21 papers
Jordi Ahnert
21 papers · 8 as a fellow
Matthew Katz
20 papers

Grants

MD Anderson Cancer Center SPORE in Gastrointestinal Cancer
National Cancer Institute · P50
Project lead · $1.4M · University of Tx Md Anderson Can Ctr
2019–2025

Clinical trials

A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.
Principal investigator · Active not recruiting · Phase 1
M.D. Anderson Cancer Center
2022–2027
Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma
Principal investigator · Terminated · Phase 1
Academic and Community Cancer Research United
2021–2023
Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer
Principal investigator · Completed · Phase 1
M.D. Anderson Cancer Center
2019–2026
First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors
Principal investigator · Completed · Phase 1
Holy Stone Healthcare Co., Ltd
2019–2022